Session Information
Date: Wednesday, June 22, 2016
Session Title: Parkinson's disease: Cognition
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: Aim of this study was to identify the degree of cognitive dysfunction in patients with subcortical Parkinsonian dementia, during the neuroprotective therapy.
Background: Parkinson’s disease is a progressive, neurodegenerative disorder which is characterized by tremor, behavioral manifestations and subcortical Parkinsonian dementia. Patients with dementia had a high risk of mortality and disability.
Methods: The study included 35 patients (24 male and 11 female) who are hospitalized in the neurology department of TMA from the (2013-2015) year, aged 41 to 76 years (middle age 56,2 ± 6,2 years) suffering with subcortical Parkinsonian dementia. To assessment neurological status used scale to assessment cognitive status the Scales for Outcomes in Parkinson’s disease-Cognition (SCOPA-COG), the Montreal Cognitive Assessment (MoCA).The patients were divided into 2 groups so as to ensure comparability of the obtained results: (control group) 17 patients took only conventional therapy, (study group) 18 patients took both amantadine 200 mg/day and Vitamin E 400 mg/day during the two months.
Results: It was found that prior to treatment, patients in the study group took 19,2 on the SCOPA-COG, and 21.3 point from the MoCA. Patients in the control group, respectively, 18.9 and 20.8. After treatment, the patients of the study group on the SCOPA-COG score increased to 25.6 points, patients in the control group score been 22.8 points. By the MoCA the study group scored 25.7 points, patients in the control group 23.4 points.
Conclusions: 1. This correlation between SCOPA-COG and MoCA provides us an easier way to determine the severity of patients with dementia and follow up progression. 2. The use of scales to determine the cognitive dysfunctions enables to improved (attention, memory and learning) identification degree of cognitive dysfunctions. 3. The use of neuroprotective drugs may be one of the alternatives for the treatment of PD in this pathology.
To cite this abstract in AMA style:
N.G. Sokhibnazarov, F.K. Shermukhamedova. Treatment with the use of the PD-specific scales for patients suffering from subcortical Parkinsonian dementia [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/treatment-with-the-use-of-the-pd-specific-scales-for-patients-suffering-from-subcortical-parkinsonian-dementia/. Accessed May 10, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/treatment-with-the-use-of-the-pd-specific-scales-for-patients-suffering-from-subcortical-parkinsonian-dementia/